piracetam and gvs 111
piracetam has been researched along with gvs 111 in 12 studies
Research
Studies (12)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bukanova, IuV; Gudasheva, TA; Ostrovskaia, RU; Skrebitskiĭ, VG; Solntseva, EI; Voronina, TA | 1 |
| Bukanova, JV; Gudasheva, TA; Ostrovskaya, RU; Skrebitsky, VG; Solntseva, EI; Voronina, TA | 1 |
| Andreeva, NA; Gudasheva, TA; Isaev, NK; Ostrovskaya, RU; Stel'mashuk, EV; Viktorov, IV | 1 |
| Akhmetova, EP; Kovalev, GI; Vorob'ev, VV | 1 |
| Bukanova, JV; Skrebitsky, VG; Solntseva, EI | 1 |
| Guzevatykh, LS; Trofimov, SS; Voronina, TA | 1 |
| Neznamov, GG; Teleshova, ES | 2 |
| Kaptsov, V; Kovalev, G; Sengpiel, F; Vorobyov, V | 1 |
| Gudasheva, TA | 1 |
| Mamchur, VI; Pavlov, SV; Zhiliuk, VI | 1 |
| Antipova, TA; Gudasheva, TA; Nikolaev, SV; Ostrovskaya, PU; Seredenin, SB | 1 |
Other Studies
12 other study(ies) available for piracetam and gvs 111
| Article | Year |
|---|---|
[Effect of the nootropic agents piracetam and GBS-111 on potential-dependent ion channels in the neuronal membrane].
Topics: Animals; Calcium Channels; Cell Membrane; Dipeptides; Helix, Snails; Ion Channels; Membrane Potentials; Neurons; Nootropic Agents; Piracetam; Potassium Channels; Sodium Channels | 1996 |
The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels.
Topics: Animals; Calcium Channels; Dipeptides; Helix, Snails; Neurons; Nootropic Agents; Patch-Clamp Techniques; Piracetam; Potassium Channels | 1997 |
Neuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stress.
Topics: 2-Amino-5-phosphonovalerate; Animals; Brain Ischemia; Cells, Cultured; Cerebellum; Dipeptides; Glucose; Glutamic Acid; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Oxygen; Piracetam; Rats; Rats, Wistar | 2000 |
[NMDA-dependent component in effects of pyracetam and GBC-111, the new peptide with the nootropic activity, on EEG in the cerebral cortex and hippocampus from non-narcotized rats].
Topics: Animals; Cerebral Cortex; Dipeptides; Electroencephalography; Excitatory Amino Acid Antagonists; Hippocampus; Nootropic Agents; Piracetam; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate | 1999 |
Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons.
Topics: Animals; Calcium Channels; Cell Separation; Dipeptides; Dose-Response Relationship, Drug; Helix, Snails; In Vitro Techniques; Membrane Potentials; Neurons; Nootropic Agents; Patch-Clamp Techniques; Piracetam; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Vinca Alkaloids | 2002 |
Early postnatal effects of noopept and piracetam on declarative and procedural memory of adult male and female rats.
Topics: Animals; Animals, Outbred Strains; Dipeptides; Female; Male; Maze Learning; Memory; Nootropic Agents; Piracetam; Rats; Reinforcement, Psychology | 2005 |
[A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin].
Topics: Adolescent; Adult; Brain Diseases; Brain Injuries; Cognition Disorders; Dipeptides; Humans; Middle Aged; Neuroprotective Agents; Nootropic Agents; Piracetam; Time Factors; Treatment Outcome | 2008 |
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.
Topics: Adolescent; Adult; Brain Diseases; Brain Injuries; Cognition Disorders; Dipeptides; Humans; Middle Aged; Neuroprotective Agents; Nootropic Agents; Piracetam; Time Factors; Treatment Outcome | 2009 |
Effects of nootropics on the EEG in conscious rats and their modification by glutamatergic inhibitors.
Topics: Animals; Brain; Dipeptides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Electroencephalography; Excitatory Amino Acid Antagonists; Male; Nootropic Agents; Piracetam; Rats; Rats, Wistar; Spectrum Analysis; Statistics, Nonparametric; Time Factors; Wakefulness | 2011 |
[Strategy for the development of dipeptide drugs].
Topics: Biological Availability; Biopharmaceutics; Blood-Brain Barrier; Dipeptides; Drug Design; Humans; Nootropic Agents; Piracetam; Proline; Protein Conformation; Psychotropic Drugs; Receptors, Cell Surface; Sulpiride; Tyrosine | 2011 |
[Role of functional state of neuronal mitochondria of cerebral cortex in mechanisms of nootropic activity of neuroprotectors in rats with alloxan hyperglycemia].
Topics: Alloxan; Amnesia; Animals; Avoidance Learning; Cerebral Cortex; Cognition; Cytidine Diphosphate Choline; Diabetes Mellitus, Experimental; Dipeptides; Hyperglycemia; Male; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Neurons; Nootropic Agents; Pentoxifylline; Piracetam; Rats; Rats, Wistar | 2015 |
Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model.
Topics: Animals; Cell Line; Cell Survival; Dipeptides; Glutamic Acid; Mice; Neurons; Neuroprotective Agents; Piracetam | 2016 |